Treace Medical Concepts Inc. has reported its first-quarter 2025 financial results, highlighting a significant growth in revenue. The company achieved a revenue figure of $230 million, marking a 7% to 10% increase compared to the full-year 2024. This performance aligns with the company's expectations of achieving a breakeven Adjusted EBITDA for the full-year 2025. Treace Medical Concepts Inc. uses Adjusted EBITDA as a key financial metric, which excludes various expenses such as depreciation, amortization, interest, taxes, and other costs. This non-GAAP measure is employed to provide a clearer picture of the company's operating results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.